Abstract

There is considerable inter-ethnic variability in the incidence of CYP2C19 genetic poor metabolisers (var/var). About 3 per cent of Caucasians are CYP2C19 var/var. By contrast, an extremely high incidence (70 per cent) is observed in the Melanesian island of Vanuatu. The colonisation of the Pacific Islands is believed to have involved migration through Papua New Guinea (PNG), and hence a high incidence may also be expected in this population. The reported incidence in PNG was only 36 per cent, however. PNG is a country of extensive ethnic diversity, and the incidence of the CYP2C19 var/var in other regional populations of PNG is currently not established. In this study, restriction fragment length polymorphism-polymerase chain reaction analysis of archival blood serum samples was used to determine the prevalence of the CYP2C19*2 and *3 variant alleles in three different ethnic and geographically isolated populations of PNG. In the largest population studied (Iruna), the frequency of both variant CYP2C19 alleles was high (0.37 and 0.34, respectively). Specifically, the frequency of the CYP2C19*3 allele was significantly higher than in the PNG (East Sepik) population reported previously (0.34 vs 0.16; p <0.0001). In the Iruna population, 48.9 per cent of the samples were homozygous variants for CYP2C19*2 or *3, which although higher was not statistically different from the East Sepik population (36 per cent). The results of this study indicated that other regional populations of PNG also have a relatively high incidence of the CYP2C19 genetic polymorphism compared with Caucasian populations. The high incidence reported in Vanuatu, however, may be due to genetic drift rather than a PNG founder population, as the Vanuatu population is dominated by the CYP2C19*2 allele, with a lower contribution from the *3 allelic variant.

Highlights

  • Poor metabolism of drugs, such as the anti-malarial agent proguanil[1] and the anti-ulcer agent omeprazole[2] is associated with genetic variants of the CYP2C19 enzyme (CYP2C19*2 and CYP2C19*3).[3]

  • It is clearly established that the *2 and *3 null alleles account for the majority of

  • We report the use of archival serum samples to determine the prevalence of the CYP2C19 *2 and *3 variant alleles in three different ethnic and geographically isolated regional populations of Papua New Guinea (PNG)

Read more

Summary

Introduction

Poor metabolism of drugs, such as the anti-malarial agent proguanil[1] and the anti-ulcer agent omeprazole[2] is associated with genetic variants of the CYP2C19 enzyme (CYP2C19*2 and CYP2C19*3).[3] The CYP2C19*2 A) variant results in a splice site mutation[4] and the CYP2C19*3 A) variant results in a premature stop codon[4] and both result in a loss of functional enzyme. There is a gene dose-dependent decrease in drug metabolism, and individuals who are homozygous wild-type, heterozygous or homozygous variant for these null alleles are termed extensive (EM), intermediate (IM) or poor (PM) metabolisers. The restriction fragment length polymorphism– polymerase chain reaction (RFLP-PCR) analysis of these variant alleles is widely used and well validated. It is clearly established that the *2 and *3 null alleles account for the majority of

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.